Summary:
A phase III, randomized, double-blind and placebo-controlled study of once daily bi 201335 120 mg for 24 weeks and bi 201335 240 mg for 12 weeks in combination with pegylated interferon-a and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection.
Qualified Participants Must:
• Be 18-70 years of age
•
Have chronic Hepatitis C
•
Have never been treated with HCV medications
•
Be willing to attend up to 13 clinic visits over 72 weeks
Qualified Participants May Receive:
Study related medical exams and follow-ups, laboratory tests, and study medications.